Aridis Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $13.94 million
- Book Value:
- Revenue TTM:
- $2.87 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Aridis Pharmaceuticals Inc had its IPO on 2018-08-10 under the ticker symbol ARDS.
The company operates in the Healthcare sector and Biotechnology industry. Aridis Pharmaceuticals Inc has a staff strength of 34 employees.
Shares of Aridis Pharmaceuticals Inc opened at $0.29 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $0.24 - $0.3, and closed at $0.29.
This is a +3.5% increase from the previous day's closing price.
A total volume of 2,718,573 shares were traded at the close of the day’s session.
In the last one week, shares of Aridis Pharmaceuticals Inc have increased by +61%.
Aridis Pharmaceuticals Inc's Key Ratios
Aridis Pharmaceuticals Inc has a market cap of $13.94 million, indicating a price to book ratio of 5.3976 and a price to sales ratio of 7.3343.
In the last 12-months Aridis Pharmaceuticals Inc’s revenue was $2.87 million with a gross profit of $-35401000 and an EBITDA of $-30581000. The EBITDA ratio measures Aridis Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aridis Pharmaceuticals Inc’s operating margin was -1086.39% while its return on assets stood at -101.84% with a return of equity of 0%.
In Q3, Aridis Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 22.5%.
Aridis Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.7 per share while it has a forward price to earnings multiple of 2.0606 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aridis Pharmaceuticals Inc’s profitability.
Aridis Pharmaceuticals Inc stock is trading at a EV to sales ratio of 17.5708 and a EV to EBITDA ratio of -1.2481. Its price to sales ratio in the trailing 12-months stood at 7.3343.
Aridis Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $12.12 million
- Total Liabilities
- $42.28 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Aridis Pharmaceuticals Inc ended 2023 with $12.12 million in total assets and $0 in total liabilities. Its intangible assets were valued at $12.12 million while shareholder equity stood at $-35823000.00.
Aridis Pharmaceuticals Inc ended 2023 with $78000.00 in deferred long-term liabilities, $42.28 million in other current liabilities, 2000.00 in common stock, $-189279000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $1.89 million and cash and short-term investments were $1.89 million. The company’s total short-term debt was $9,152,000 while long-term debt stood at $3.50 million.
Aridis Pharmaceuticals Inc’s total current assets stands at $8.64 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $248000.00 compared to accounts payable of $4.23 million and inventory worth $0.
In 2023, Aridis Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Aridis Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Aridis Pharmaceuticals Inc stock is currently trading at $0.29 per share. It touched a 52-week high of $2.77 and a 52-week low of $2.77. Analysts tracking the stock have a 12-month average target price of $6.
Its 50-day moving average was $0.24 and 200-day moving average was $0.81 The short ratio stood at 0.29 indicating a short percent outstanding of 0%.
Around 4026.2% of the company’s stock are held by insiders while 1988.2% are held by institutions.
Frequently Asked Questions About Aridis Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.